Company profile: PLx Pharma
1.1 - Company Overview
Company description
- Provider of non-steroidal anti-inflammatory drugs for prescription and over-the-counter markets, developing and commercializing these therapies.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PLx Pharma
Lipocine
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products, including TLANDO, an FDA-approved oral testosterone replacement therapy; LPCN 1111, an oral testosterone prodrug for hypogonadal men; LPCN 1144 and 1148, oral prodrugs of bioidentical testosterone for NASH and cirrhosis symptoms; LPCN 1107, an oral candidate to prevent recurrent preterm birth (FDA orphan drug); and LPCN 1154, an oral neurosteroid for postpartum depression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lipocine company profile →
H&T Presspart
HQ: United Kingdom
Website
- Description: Provider of drug delivery devices and manufacturing services for asthma and COPD, offering metered-dose inhalation devices and components (actuators, dose counters), dry powder inhalers including PowdAir Plus, comprehensive drug delivery device development from design to manufacturing, high-precision injection moulding, automated multi-component assembly, and deep drawing of metal components such as MDI cans.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full H&T Presspart company profile →
Nu-Med Plus
HQ: United States
Website
- Description: Provider of patented medical device technology to safely deliver precision doses of nitric oxide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nu-Med Plus company profile →
Elektrofi
HQ: United States
Website
- Description: Provider of a microparticle platform (Hypercon) enabling low-volume, stable, hyper-concentrated biologic formulations for subcutaneous delivery, alongside formulation development services—covering process development, formulation, analytics, and innovation—and partnership programs with pharmaceutical companies to develop and commercialize subcutaneous biologic therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elektrofi company profile →
Oval Medical Technologies
HQ: United States
Website
- Description: Provider of specialty pharmaceutical autoinjector platforms: ArQ subcutaneous two-step autoinjector with audible feedback, compatible with various viscosities, volumes, and needle gauges; Bios platform for large-volume, ultra-high viscosity formulations using ISO-standard plunger stoppers and staked-needle syringes; Vita resuspension platform for delivering large volumes with a dry-needle system for long-acting formulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oval Medical Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PLx Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PLx Pharma
2.2 - Growth funds investing in similar companies to PLx Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PLx Pharma
4.2 - Public trading comparable groups for PLx Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →